Flagship therapy push, Hanmi Pharm’s Rolontis steps into wider global use

Long-acting G-CSF drug Rolontis is Hanmi Pharm’s flagship biologic, designed to reduce chemotherapy-induced neutropenia with a single injection per cycle. Recent approvals and licensing deals show how the Korean company is betting on this product as a key growth pillar.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 9:22 AM ET. Details in the imprint.

Hanmi Pharm’s long-acting neutropenia drug Rolontis is quietly becoming one of the company’s most important flagship therapies, as the pegylated G-CSF continues to expand its commercial footprint in cancer care markets beyond South Korea.

Marketed domestically under the name Rolontis and licensed abroad to partners, the biologic is indicated to reduce the duration of severe neutropenia in patients receiving cytotoxic chemotherapy, positioning it directly against entrenched brands like Amgen’s Neulasta and various pegfilgrastim biosimilars.

With once-per-chemotherapy-cycle dosing, Rolontis aims to cut infection risk and hospitalizations for patients whose white blood cell counts are heavily suppressed by standard oncology regimens.

What Rolontis does and how it is designed to work

Rolontis (eflapegrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) designed for adults with non-myeloid malignancies who are at risk of febrile neutropenia due to myelosuppressive chemotherapy.

The active substance, eflapegrastim, links a G-CSF analog to a long-acting Fc fragment, a structural approach intended to extend circulation time in the body while driving robust stimulation of neutrophil production in the bone marrow.

Hanmi Pharm first developed the molecule and later licensed ex-Korea rights to Spectrum Pharmaceuticals, which in turn brought the drug to the US market as Rolvedon after securing approval from the Food and Drug Administration for reducing the incidence of infection, as manifested by febrile neutropenia, in adults receiving certain cytotoxic chemotherapy for non-myeloid cancers.

South Korean regulators had already cleared Rolontis for local use, establishing the drug as one of Hanmi’s flagship biologics in its home oncology portfolio and giving the company a reference point for subsequent international submissions.

In pivotal clinical trials against existing pegfilgrastim products, eflapegrastim demonstrated non-inferiority in key outcomes such as duration of severe neutropenia and incidence of febrile neutropenia, supporting its positioning as an alternative long-acting G-CSF option for oncologists.

Those studies typically followed a single subcutaneous injection per chemotherapy cycle, administered around 24 hours after cytotoxic treatment, aligning with familiar practice patterns in supportive oncology care.

From a patient perspective, the promise is straightforward: maintain adequate neutrophil counts with one injection each cycle, minimizing the need for additional injections or unscheduled visits while reducing the risk of potentially life-threatening infections.

Key product features and competitive landscape

Unlike daily filgrastim injections, Rolontis is formulated for once-per-cycle administration, relying on its Fc-based half-life extension technology to match or exceed the exposure profile of conventional pegfilgrastim-based products.

The drug is available as a prefilled syringe, a format that allows subcutaneous administration in hospital outpatient settings or cancer centers and, in some healthcare systems, supervised home use when permitted by local practice.

Hanmi Pharm emphasizes that the extended-activity design seeks not only to maintain neutrophil counts but also to reduce the duration of grade 4 neutropenia, a period when patients are most vulnerable to serious infections and febrile episodes.

In markets where Rolontis or its partnered brands compete directly with originator pegfilgrastim and biosimilars, pricing and reimbursement terms vary by country, but the drug is generally positioned as a cost-conscious alternative within the long-acting G-CSF class rather than a premium-priced novel category.

This positioning reflects the reality that oncologists already have multiple options for prophylactic neutropenia management, making clinical non-inferiority and economic competitiveness key drivers for formulary inclusion and real-world uptake.

For Hanmi, however, Rolontis stands out because it is one of the first biologics fully developed in-house to secure approvals beyond its home market, turning the drug into a strategic reference point as the company moves deeper into oncology and biologics-based pipelines.

That shift is visible in the company’s broader R&D messaging, where anti-cancer, obesity and metabolic disease programs are increasingly paired with long-term ambitions in anti-aging and so-called “reverse aging” therapeutics as future growth engines.

Distribution, indications and regional specifics

In South Korea, Rolontis is used as supportive care in adult cancer patients receiving cytotoxic chemotherapy, with prescribing information emphasizing the goal of reducing the duration of severe neutropenia and the incidence of febrile neutropenia.

The medication is typically covered under national health insurance for indicated chemotherapy regimens, making it accessible in major university hospitals and oncology centers across the country.

Outside Korea, commercialization has relied on licensing partners, which adapt branding and regulatory dossiers to local standards, a strategy that allows Hanmi to monetize the asset without building its own large sales infrastructure in each market.

In the US, the licensed version of eflapegrastim is indicated for adults with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, mirroring typical label language in the G-CSF class.

Administration protocols in those markets generally follow established guidelines for supportive care in chemotherapy, including timing relative to cytotoxic agents and contraindications such as hypersensitivity to G-CSF analogs.

Real-world use also reflects the standard cautionary notes for long-acting G-CSF therapy, including the need to monitor for bone pain, splenic enlargement and rare but serious adverse events such as splenic rupture or acute respiratory distress syndrome.

From a commercial perspective, the drug’s value proposition hinges on demonstrating comparable safety and efficacy to existing long-acting G-CSF products, while offering health systems potential cost savings or supply diversification.

Strategic relevance for Hanmi Pharm

Rolontis occupies a central position in Hanmi Pharm’s strategy to evolve from a largely domestic-focused player into a biotech with multiple global revenue streams based on proprietary molecules rather than generics alone.

The company has consistently highlighted biologics and targeted therapies as growth pillars, and the international traction of eflapegrastim helps validate its underlying drug discovery and antibody engineering platforms.

Success with Rolontis also supports Hanmi’s ambition to expand its portfolio in oncology and metabolic disease, areas where the firm sees opportunities to pair small molecules with biologic agents and, over the longer term, integrate anti-aging research.

In financial terms, while the drug is not yet a megablockbuster, it represents a meaningful contribution to Hanmi’s specialty pharma revenues, especially in the context of royalty and milestone streams from overseas partners.

Management has indicated in various communications that expanding indications and geographical coverage for key assets like Rolontis will be critical to driving steady topline growth amid competitive pressure in established therapeutic categories.

Investors therefore tend to watch updates around Rolontis approvals, reimbursement decisions and partner sales trends as indicators of how well Hanmi is executing its shift toward higher-value specialty and biologic drugs.

Shares of Hanmi Pharmaceutical (ISIN KR7128940004) last traded on the Korea Exchange in Seoul in Korean won, reflecting investor expectations around the company’s ability to scale products like Rolontis alongside its broader anti-cancer and metabolic pipeline.

Rolontis in brief: key facts for patients and investors

• Product: Rolontis (eflapegrastim)
• Manufacturer: Hanmi Pharmaceutical Co.
• Category: Flagship/Bestseller oncology supportive-care biologic
• Launch date: Initial South Korea launch after domestic approval; subsequent rollouts via partners in selected global markets
• MSRP / Price: Reimbursed specialty biologic; pricing varies by market and reimbursement system
• Availability: Oncology and hematology centers in South Korea and selected international markets via licensing partners
• Target audience: Adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy and at risk of febrile neutropenia
• Key differentiator / USP: Long-acting G-CSF analog developed by Hanmi, administered once per chemotherapy cycle to reduce duration of severe neutropenia

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.